Madrigal Posts Soaring Rezdiffra Sales, Expands Pipeline With GLP-1 Partnership
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported strong third-quarter 2025 results, fueled by accelerating sales of its liver disease drug Rezdiffra™ (resmetirom) and a major expansion of its …
Madrigal Posts Soaring Rezdiffra Sales, Expands Pipeline With GLP-1 Partnership Read More